{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T09:05:02Z","timestamp":1789635902890,"version":"4.0.0"},"reference-count":135,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Bone metastases are common in advanced solid tumors and are clinically important not only because they cause skeletal-related events, including bone pain, pathological fractures, and spinal cord compression, but also because they may influence responses to immune checkpoint inhibitors (ICIs). Clinical evidence has consistently associated bone metastases with poorer survival after ICI treatment. Although some studies suggest that the relative benefit of ICIs may be reduced in patients with bone metastases, most available evidence is retrospective and lacks adequate treatment-interaction testing. This apparent reduction in benefit therefore cannot be clearly distinguished from adverse baseline prognosis, greater disease burden, or confounding related to concomitant treatments. Lesion-level studies further suggest that bone and nonbone lesions may follow discordant response trajectories. Assessment of bone-lesion response is complicated by the limited measurability of bone-only lesions under RECIST 1.1 and by treatment-related sclerosis, bone flare, and mixed responses. Mechanistically, bone metastases may establish a site-specific osteoimmune niche in which abnormal bone remodeling, vascular and stromal reorganization, myeloid immunosuppression, and impaired T-cell infiltration and effector function jointly constrain local antitumor immunity. RANKL inhibition and bone-directed radiotherapy are clinically available and may have immunomodulatory effects, but current evidence does not establish that either approach consistently enhances the antitumor activity of ICIs beyond skeletal protection or local control. Most other microenvironment-directed strategies remain at the preclinical or early translational stage. Future studies should distinguish bone-lesion antitumor response from systemic disease control and skeletal clinical outcomes. Prespecified treatment-interaction analyses, longitudinal multimodal imaging, paired sampling of bone and nonbone lesions, and mechanism-embedded clinical trials will be required to determine whether specific osteoimmune niche states can guide patient selection and combination therapy.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1959101","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T08:40:13Z","timestamp":1789634413000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Immune checkpoint inhibition in bone metastases: lesion response heterogeneity, the osteoimmune niche, and microenvironment-directed therapy"],"prefix":"10.3389","volume":"17","author":[{"given":"Min","family":"Dong","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, The 960th Hospital of the People's Liberation Army (PLA) Joint Logistic Support Force","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guili","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The 960th Hospital of the People's Liberation Army (PLA) Joint Logistic Support Force","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangyuan","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The 960th Hospital of the People's Liberation Army (PLA) Joint Logistic Support Force","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Yin","sequence":"additional","affiliation":[{"name":"Jinzhou Medical University","place":["Jinzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The 960th Hospital of the People's Liberation Army (PLA) Joint Logistic Support Force","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.7668","article-title":"Bone metastases, skeletal-related events, and survival in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors","volume":"19","author":"Qin","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1493773","article-title":"Impact of bone metastasis on prognosis in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"15","author":"Zhu","year":"2024","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2022.03.006","article-title":"Bone metastasis attenuates efficacy of immune checkpoint inhibitors and displays \"cold\" immune characteristics in non-small cell lung cancer","volume":"166","author":"Zhu","year":"2022","journal-title":"Lung Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s40425-019-0793-8","article-title":"Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer","volume":"7","author":"Landi","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13597","article-title":"Adverse impact of bone metastases on clinical outcomes of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors","volume":"11","author":"Li","year":"2020","journal-title":"Thorac Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2239-4","article-title":"Organ-specific response to nivolumab in patients with non-small cell lung cancer (Nsclc)","volume":"67","author":"Schmid","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2020.11856","article-title":"Early response of bone metastases can predict tumor response in patients with non-small-cell lung cancer with bone metastases in the treatment with nivolumab","volume":"20","author":"Nakata","year":"2020","journal-title":"Oncol Lett"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03180-x","article-title":"Evolution of bone metastases in patients receiving at least three months of checkpoint inhibitors","volume":"71","author":"Gefard-Gontier","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605546","article-title":"Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer","volume":"102","author":"Hamaoka","year":"2010","journal-title":"Br J Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised recist guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01098","article-title":"Efficacy of immune checkpoint inhibitors in non-small-cell lung cancer patients with different metastatic sites: A systematic review and meta-analysis","volume":"10","author":"Yang","year":"2020","journal-title":"Front Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1379056","article-title":"Effectiveness of immune checkpoint inhibitor therapy on bone metastases in non-small-cell lung cancer","volume":"15","author":"Abbott","year":"2024","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00590-024-04018-1","article-title":"Response rate specific to bone metastasis of various cancers for immune checkpoint inhibitors: A systematic review","volume":"34","author":"Tsukamoto","year":"2024","journal-title":"Eur J Orthop Surg Traumatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16112136","article-title":"Site-specific response and resistance patterns in patients with advanced non-small-cell lung cancer treated with first-line systemic therapy","volume":"16","author":"Brown","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/ph17121591","article-title":"Immunotherapy in the battle against bone metastases: Mechanisms and emerging treatments","volume":"17","author":"Hamza","year":"2024","journal-title":"Pharm (Basel)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-024-01256-7","article-title":"Immunotherapy in the fight against bone metastases: A review of recent developments and challenges","volume":"25","author":"Peng","year":"2024","journal-title":"Curr Treat Options Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/8970173","article-title":"Immune checkpoint inhibitor therapy for bone metastases: Specific microenvironment and current situation","volume":"2021","author":"Liu","year":"2021","journal-title":"J Immunol Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2023.100505","article-title":"Immune checkpoint inhibitors in bone metastasis: Clinical challenges, toxicities, and mechanisms","volume":"43","author":"Joseph","year":"2023","journal-title":"J Bone Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23126832","article-title":"Bone metastasis and immune checkpoint inhibitors in non-small cell lung cancer (Nsclc): Microenvironment and possible clinical implications","volume":"23","author":"Del Conte","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s11914-023-00798-3","article-title":"Checkpoint inhibitors in bone metastatic disease in solid tumors","volume":"21","author":"Wytiaz","year":"2023","journal-title":"Curr Osteoporos Rep"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2023.09.002","article-title":"Bone-modifying agents for non-small-cell lung cancer patients with bone metastases during the era of immune checkpoint inhibitors: A narrative review","volume":"50","author":"Kim","year":"2023","journal-title":"Semin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1177\/10732748261427063","article-title":"Denosumab plus immune checkpoint inhibitors in bone metastases from solid tumors","volume":"33","author":"Wang","year":"2026","journal-title":"Cancer Control"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/cells10061529","article-title":"Osteoimmuno-oncology: Therapeutic opportunities for targeting immune cells in bone metastasis","volume":"10","author":"K\u00e4hk\u00f6nen","year":"2021","journal-title":"Cells"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1177\/11795549251338144","article-title":"Efficacy of immunotherapy in patients with bone metastases from driver gene-negative non-small-cell lung cancer: A systematic review and meta-analysis of randomized controlled trials","volume":"19","author":"Zhao","year":"2025","journal-title":"Clin Med Insights Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.02.010","article-title":"Checkmate 025 randomized phase 3 study: Outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma","volume":"72","author":"Escudier","year":"2017","journal-title":"Eur Urol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1177\/17588359211019642","article-title":"Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: The development of a novel prognostic score (Meet-Uro 15 study)","volume":"13","author":"Rebuzzi","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102215","article-title":"Prognostic impact of bone metastasis in patients with metastatic urothelial carcinoma treated with durvalumab with or without tremelimumab in the Danube study","volume":"22","author":"Stecca","year":"2024","journal-title":"Clin Genitourin Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14071735","article-title":"Organ-specific and mixed responses to pembrolizumab in patients with unresectable or metastatic urothelial carcinoma: A multicenter retrospective study","volume":"14","author":"Shimizu","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/cncr.32522","article-title":"Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-Pd-1 therapy","volume":"126","author":"Pires da Silva","year":"2020","journal-title":"Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5468","article-title":"Five-year survival and clinical correlates among patients with advanced non-small cell lung cancer, melanoma and renal cell carcinoma treated with immune check-point inhibitors in Australian tertiary oncology centres","volume":"12","author":"Brown","year":"2023","journal-title":"Cancer Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.5312\/wjo.v15.i12.1155","article-title":"Prognostic factors in patients with bone metastasis of lung cancer after immune checkpoint inhibitors: A retrospective study","volume":"15","author":"Ishibashi","year":"2024","journal-title":"World J Orthop"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2022.03.008","article-title":"Long-term survival of patients with non-small cell lung cancer treated with immune checkpoint inhibitor monotherapy in real-world settings","volume":"23","author":"Yoneda","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107417","article-title":"High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors","volume":"186","author":"Manglaviti","year":"2023","journal-title":"Lung Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.cllc.2020.10.002","article-title":"Differential efficacy of pembrolizumab according to metastatic sites in patients with Pd-L1 strongly positive (Tps \u2265 50%) Nsclc","volume":"22","author":"Takeyasu","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-019-00882-5","article-title":"Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high Pd-L1 expression: A retrospective multicenter cohort study","volume":"38","author":"Kawachi","year":"2020","journal-title":"Invest New Drugs"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-21-1502","article-title":"Bone metastases in non-small cell lung cancer: A narrative review","volume":"14","author":"Knapp","year":"2022","journal-title":"J Thorac Dis"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4391","article-title":"Individualized bone-protective management in long-term cancer survivors with bone metastases","volume":"36","author":"Rachner","year":"2021","journal-title":"J Bone Miner Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.07.019","article-title":"Bone health in cancer: Esmo clinical practice guidelines","volume":"31","author":"Coleman","year":"2020","journal-title":"Ann Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20020280","article-title":"Bone metastasis pain, from the bench to the bedside","volume":"20","author":"Aielli","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B40","doi-asserted-by":"publisher","first-page":"482","DOI":"10.21037\/atm.2020.03.55","article-title":"Incidence of patients with bone metastases at diagnosis of solid tumors in adults: A large population-based study","volume":"8","author":"Huang","year":"2020","journal-title":"Ann Transl Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-069908","article-title":"Prevalence and prognosis of bone metastases in common solid cancers at initial diagnosis: A population-based study","volume":"13","author":"Zhang","year":"2023","journal-title":"BMJ Open"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1668","article-title":"Incidence proportions and prognosis of breast cancer patients with bone metastases at initial diagnosis","volume":"7","author":"Gong","year":"2018","journal-title":"Cancer Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2012.12.004","article-title":"Incidence and consequences of bone metastases in lung cancer patients","volume":"2","author":"Kuchuk","year":"2013","journal-title":"J Bone Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318206a1e3","article-title":"Epidemiology and treatment costs of bone metastases from lung cancer: A French prospective, observational, multicenter study (Gfpc 0601)","volume":"6","author":"Decroisette","year":"2011","journal-title":"J Thorac Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-023-03300-8","article-title":"Impact of bone metastasis on the prognosis of non-small cell lung cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"26","author":"Liu","year":"2024","journal-title":"Clin Transl Oncol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"87","DOI":"10.21037\/tlcr-21-1033","article-title":"Pembrolizumab monotherapy or combination therapy for bone metastases in advanced non-small cell lung cancer: A real-world retrospective study","volume":"11","author":"Qiang","year":"2022","journal-title":"Transl Lung Cancer Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-22-350","article-title":"A cohort study of the efficacy and safety of immune checkpoint inhibitors plus anlotinib versus immune checkpoint inhibitors alone as the treatment of advanced non-small cell lung cancer in the real world","volume":"11","author":"Shi","year":"2022","journal-title":"Transl Lung Cancer Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2241310","article-title":"Effects of combining immune checkpoint inhibitors and anti-angiogenic agents on bone metastasis in non-small cell lung cancer patients","volume":"19","author":"Xie","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.00709","article-title":"Lesion-level response dynamics to programmed cell death protein (Pd-1) blockade","volume":"37","author":"Osorio","year":"2019","journal-title":"J Clin Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1097\/cm9.0000000000002217","article-title":"Organ-specific efficacy in advanced non-small cell lung cancer patients treated with first-line single-agent immune checkpoint inhibitors","volume":"135","author":"Deng","year":"2022","journal-title":"Chin Med J (Engl)"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.871675","article-title":"The therapeutic effect and clinical outcome of immune checkpoint inhibitors on bone metastasis in advanced non-small-cell lung cancer","volume":"12","author":"Asano","year":"2022","journal-title":"Front Oncol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1053\/j.semnuclmed.2014.07.004","article-title":"Evaluation of osseous metastasis in bone scintigraphy","volume":"45","author":"Davila","year":"2015","journal-title":"Semin Nucl Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(17)30074-8","article-title":"Irecist: Guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"80","DOI":"10.7150\/jca.1.80","article-title":"Cancer response criteria and bone metastases: Recist 1.1, mda and percist","volume":"1","author":"Costelloe","year":"2010","journal-title":"J Cancer"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-022-04120-z","article-title":"Bone-specific response according to mda criteria predicts immunotherapy efficacy among advanced non-small cell lung cancer (nsclc) patients","volume":"149","author":"De Giglio","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605825","article-title":"Assessment of therapeutic response in patients with metastatic skeletal disease: Suggested modifications for the mda response classification criteria","volume":"103","author":"Vassiliou","year":"2010","journal-title":"Br J Cancer"},{"key":"B57","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/sj.bjc.6605826","article-title":"Reply: Assessment of therapeutic response in patients with metastatic skeletal disease: Suggested modifications for the mda response classification criteria","volume":"103","author":"Hamaoka","year":"2010","journal-title":"Br J Cancer"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2013.09.001","article-title":"Incidence, consequences and treatment of bone metastases in breast cancer patients-experience from a single cancer centre","volume":"2","author":"Kuchuk","year":"2013","journal-title":"J Bone Oncol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1152\/physrev.00012.2019","article-title":"Bone metastasis: Mechanisms, therapies, and biomarkers","volume":"101","author":"Cl\u00e9zardin","year":"2021","journal-title":"Physiol Rev"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a036848","article-title":"Bone tropism in cancer metastases","volume":"10","author":"Wang","year":"2020","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1172\/jci143764","article-title":"Exploiting bone niches: Progression of disseminated tumor cells to metastasis","volume":"131","author":"Muscarella","year":"2021","journal-title":"J Clin Invest"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2011.47","article-title":"Bone marrow and the control of immunity","volume":"9","author":"Zhao","year":"2012","journal-title":"Cell Mol Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3390\/cells13090724","article-title":"Bone marrow adipose tissue","volume":"13","author":"Marinelli Busilacchi","year":"2024","journal-title":"Cells"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00036.2016","article-title":"Osteoimmunology: The conceptual framework unifying the immune and skeletal systems","volume":"97","author":"Okamoto","year":"2017","journal-title":"Physiol Rev"},{"key":"B65","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/nri2062","article-title":"Osteoimmunology: Shared mechanisms and crosstalk between the immune and bone systems","volume":"7","author":"Takayanagi","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017.213","article-title":"Updating osteoimmunology: Regulation of bone cells by innate and adaptive immunity","volume":"14","author":"Walsh","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/720504","article-title":"The interplay between the bone and the immune system","volume":"2013","author":"Mori","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.R109.041087","article-title":"Cellular and molecular mechanisms of bone remodeling","volume":"285","author":"Raggatt","year":"2010","journal-title":"J Biol Chem"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.31036","article-title":"Fine-tuning osteoclastogenesis: An insight into the cellular and molecular regulation of osteoclastogenesis","volume":"238","author":"Anwar","year":"2023","journal-title":"J Cell Physiol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242216175","article-title":"Role and regulation of transcription factors in osteoclastogenesis","volume":"24","author":"Jiang","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1242\/dev.199908","article-title":"The origins and roles of osteoclasts in bone development, homeostasis and repair","volume":"149","author":"Yahara","year":"2022","journal-title":"Development"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02182","article-title":"Chemokines in physiological and pathological bone remodeling","volume":"10","author":"Brylka","year":"2019","journal-title":"Front Immunol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1159\/000489184","article-title":"Molecular regulation of bone metastasis pathogenesis","volume":"46","author":"Wu","year":"2018","journal-title":"Cell Physiol Biochem"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1172\/jci43414","article-title":"Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow","volume":"121","author":"Shiozawa","year":"2011","journal-title":"J Clin Invest"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2503","article-title":"E-selectin ligand-1 controls circulating prostate cancer cell rolling\/adhesion and metastasis","volume":"5","author":"Yasmin-Karim","year":"2014","journal-title":"Oncotarget"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/embor.2012.41","article-title":"The pro-metastatic role of bone marrow-derived cells: A focus on mscs and regulatory t cells","volume":"13","author":"Koh","year":"2012","journal-title":"EMBO Rep"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/nrc867","article-title":"Metastasis to bone: Causes, consequences and therapeutic opportunities","volume":"2","author":"Mundy","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N Engl J Med"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-06-1007","article-title":"Basic mechanisms responsible for osteolytic and osteoblastic bone metastases","volume":"12","author":"Guise","year":"2006","journal-title":"Clin Cancer Res"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v5.i2.149","article-title":"Bone metastases: When and how lung cancer interacts with bone","volume":"5","author":"Roato","year":"2014","journal-title":"World J Clin Oncol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10020056","article-title":"Cancer stem cells, bone and tumor microenvironment: Key players in bone metastases","volume":"10","author":"Roato","year":"2018","journal-title":"Cancers (Basel)"},{"key":"B82","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/bcr2781","article-title":"Breast cancer metastasis to the bone: Mechanisms of bone loss","volume":"12","author":"Chen","year":"2010","journal-title":"Breast Cancer Res"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2402903121","article-title":"Prostate cancer-induced endothelial-cell-to-osteoblast transition drives immunosuppression in the bone-tumor microenvironment through wnt pathway-induced m2 macrophage polarization","volume":"121","author":"Yu","year":"2024","journal-title":"Proc Natl Acad Sci USA"},{"key":"B84","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1186\/s40425-019-0753-3","article-title":"Distinct tumor microenvironments of lytic and blastic bone metastases in prostate cancer patients","volume":"7","author":"Ihle","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1007\/s11538-018-0416-4","article-title":"Size matters: Metastatic cluster size and stromal recruitment in the establishment of successful prostate cancer to bone metastases","volume":"80","author":"Araujo","year":"2018","journal-title":"Bull Math Biol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3390\/cells11244081","article-title":"Sfrp2 overexpression induces an osteoblast-like phenotype in prostate cancer cells","volume":"11","author":"Akova \u00d6lken","year":"2022","journal-title":"Cells"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1038\/s41467-020-15404-8","article-title":"Tgf\u03b2 suppresses cd8(+) t cell expression of cxcr3 and tumor trafficking","volume":"11","author":"Gunderson","year":"2020","journal-title":"Nat Commun"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3390\/biom11111643","article-title":"The role of tgf-\u03b2 in bone metastases","volume":"11","author":"Trivedi","year":"2021","journal-title":"Biomolecules"},{"key":"B89","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4236\/abb.2013.410A4003","article-title":"Role of tgf-\u03b2 in breast cancer bone metastases","volume":"4","author":"Chiechi","year":"2013","journal-title":"Adv Biosci Bio\/Technol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s40001-023-01083-w","article-title":"Metastasis of breast cancer to bones alters the tumor immune microenvironment","volume":"28","author":"Chao","year":"2023","journal-title":"Eur J Med Res"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20040999","article-title":"The contribution of the immune system in bone metastasis pathogenesis","volume":"20","author":"Xiang","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.Mct-20-0378","article-title":"Rankl-targeted combination therapy with osteoprotegerin variant devoid of trail binding exerts biphasic effects on skeletal remodeling and antitumor immunity","volume":"19","author":"Wang","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4615","article-title":"Bone microenvironment-suppressed t cells increase osteoclast formation and osteolytic bone metastases in mice","volume":"37","author":"Arellano","year":"2022","journal-title":"J Bone Miner Res"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.763846","article-title":"Cross talk between macrophages and cancer cells in the bone metastatic environment","volume":"12","author":"Batoon","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2016.03.004","article-title":"The role of tumour-associated macrophages in bone metastasis","volume":"5","author":"Sousa","year":"2016","journal-title":"J Bone Oncol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1139683","article-title":"The role of myeloid derived suppressor cells in musculoskeletal disorders","volume":"14","author":"Ren","year":"2023","journal-title":"Front Immunol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1002\/mc.23192","article-title":"Integrating the immune microenvironment of prostate cancer induced bone disease","volume":"59","author":"Ihle","year":"2020","journal-title":"Mol Carcinog"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1210\/js.2018-00425","article-title":"Mechanisms of osteoblastic bone metastasis in prostate cancer: Role of prostatic acid phosphatase","volume":"3","author":"Quiroz-Munoz","year":"2019","journal-title":"J Endocr Soc"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12526","article-title":"Gene expression profiles define molecular subtypes of prostate cancer bone metastases with different outcomes and morphology traceable back to the primary tumor","volume":"13","author":"Thysell","year":"2019","journal-title":"Mol Oncol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1002\/mc.23541","article-title":"Heterogeneity in the immune microenvironment of bone metastasis in driver-positive non-small cell lung cancer","volume":"62","author":"Yang","year":"2023","journal-title":"Mol Carcinog"},{"key":"B101","doi-asserted-by":"publisher","first-page":"13838","DOI":"10.1038\/s41598-020-70788-3","article-title":"Bone metastasis is associated with acquisition of mesenchymal phenotype and immune suppression in a model of spontaneous breast cancer metastasis","volume":"10","author":"Monteran","year":"2020","journal-title":"Sci Rep"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1111\/ecc.12541","article-title":"Meta-analysis comparing denosumab and zoledronic acid for treatment of bone metastases in patients with advanced solid tumours","volume":"26","author":"Zheng","year":"2017","journal-title":"Eur J Cancer Care (Engl)"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1159\/000368710","article-title":"Bone-targeted therapy in metastatic breast cancer - all well-established knowledge","volume":"9","author":"Gampenrieder","year":"2014","journal-title":"Breast Care (Basel)"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.824117","article-title":"Roles of the Rankl-Rank axis in immunity-implications for pathogenesis and treatment of bone metastasis","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2013.00329","article-title":"Effects of Rankl-targeted therapy in immunity and cancer","volume":"3","author":"Cheng","year":"2014","journal-title":"Front Oncol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107858","article-title":"Combination therapy with immune checkpoint inhibitors and denosumab improves clinical outcomes in non-small cell lung cancer with bone metastases","volume":"193","author":"Asano","year":"2024","journal-title":"Lung Cancer"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-21-150","article-title":"Does denosumab offer survival benefits? -Our experience with denosumab in metastatic non-small cell lung cancer patients treated with immune-checkpoint inhibitors","volume":"13","author":"Cao","year":"2021","journal-title":"J Thorac Dis"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-019-02353-5","article-title":"Combination of denosumab and immune checkpoint inhibition: Experience in 29 patients with metastatic melanoma and bone metastases","volume":"68","author":"Angela","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2018.1480301","article-title":"An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer","volume":"7","author":"Liede","year":"2018","journal-title":"Oncoimmunology"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2024.100634","article-title":"Synergistic effect between denosumab and immune checkpoint inhibitors (Ici)? A retrospective study of 268 patients with Ici and bone metastases","volume":"48","author":"Mabrut","year":"2024","journal-title":"J Bone Oncol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-018-3947-x","article-title":"Eanm guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides","volume":"45","author":"Handkiewicz-Junak","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2018.05.107","article-title":"Combining immunotherapy and radiotherapy in lung cancer","volume":"10","author":"Bhalla","year":"2018","journal-title":"J Thorac Dis"},{"key":"B113","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s40425-018-0361-7","article-title":"Radiation therapy and Pd-1\/Pd-L1 blockade: The clinical development of an evolving anticancer combination","volume":"6","author":"Gong","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00185","article-title":"Combining immunotherapy and radiotherapy for cancer treatment: Current challenges and future directions","volume":"9","author":"Wang","year":"2018","journal-title":"Front Pharmacol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00612","article-title":"Radiation, immune checkpoint blockade and the abscopal effect: A critical review on timing, dose and fractionation","volume":"8","author":"Buchwald","year":"2018","journal-title":"Front Oncol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.29620","article-title":"A review of the abscopal effect in the era of immunotherapy","volume":"14","author":"Nabrinsky","year":"2022","journal-title":"Cureus"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2018.06.001","article-title":"Immunological mechanisms responsible for radiation-induced abscopal effect","volume":"39","author":"Rodr\u00edguez-Ruiz","year":"2018","journal-title":"Trends Immunol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2018.6","article-title":"Using immunotherapy to boost the abscopal effect","volume":"18","author":"Ngwa","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"B119","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ijrobp.2020.04.023","article-title":"The promise of combining radiation therapy with immunotherapy","volume":"108","author":"Jagodinsky","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djs629","article-title":"Combining radiotherapy and cancer immunotherapy: A paradigm shift","volume":"105","author":"Formenti","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.5114\/jcb.2019.89365","article-title":"Abscopal effect of high-dose-rate brachytherapy on pelvic bone metastases from renal cell carcinoma: A case report","volume":"11","author":"Suzuki","year":"2019","journal-title":"J Contemp Brachytherapy"},{"key":"B122","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s13014-021-01920-4","article-title":"True abscopal effect in a patient with metastatic non-small cell lung cancer","volume":"16","author":"Vilinovszki","year":"2021","journal-title":"Radiat Oncol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01652","article-title":"An Italian retrospective survey on bone metastasis in melanoma: Impact of immunotherapy and radiotherapy on survival","volume":"10","author":"Mannavola","year":"2020","journal-title":"Front Oncol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202201451","article-title":"Genetically engineered hematopoietic stem cells deliver Tgf-B inhibitor to enhance bone metastases immunotherapy","volume":"9","author":"Wang","year":"2022","journal-title":"Adv Sci (Weinh)"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34457","article-title":"Dynamics of Cxcr4 positive circulating tumor cells in prostate cancer patients during radiotherapy","volume":"152","author":"Klusa","year":"2023","journal-title":"Int J Cancer"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2023.1259336","article-title":"Cabozantinib and Il-27 combinatorial therapy for bone-metastatic prostate cancer","volume":"10","author":"Kumar","year":"2023","journal-title":"Front Mol Biosci"},{"key":"B127","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s40259-015-0122-9","article-title":"Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer","volume":"29","author":"Hillerdal","year":"2015","journal-title":"BioDrugs"},{"key":"B128","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/s41571-021-00499-9","article-title":"Novel approaches to target the microenvironment of bone metastasis","volume":"18","author":"Hofbauer","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B129","doi-asserted-by":"publisher","first-page":"5889","DOI":"10.1038\/s41598-020-62039-2","article-title":"Targeting of radioactive platinum-bisphosphonate anticancer drugs to bone of high metabolic activity","volume":"10","author":"Nadar","year":"2020","journal-title":"Sci Rep"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5952","article-title":"Novel predictors of immune checkpoint inhibitor response and prognosis in advanced non-small-cell lung cancer with bone metastasis","volume":"12","author":"Asano","year":"2023","journal-title":"Cancer Med"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102085","article-title":"Clinical features affecting survival in metastatic Nsclc treated with immunotherapy: A critical review of published data","volume":"89","author":"Passaro","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112276","article-title":"Combining dynamics of serum inflammatory and nutritional indicators as novel biomarkers in immune checkpoint inhibitor treatment of non-small-cell lung cancer with bone metastases","volume":"136","author":"Asano","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.17278","article-title":"Serum inflammatory dynamics as novel biomarkers for immune checkpoint inhibitors in non-small-cell lung cancer with bone metastases","volume":"44","author":"Asano","year":"2024","journal-title":"Anticancer Res"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2016.4977","article-title":"Rankl: A promising circulating marker for bone metastasis response","volume":"12","author":"Ibrahim","year":"2016","journal-title":"Oncol Lett"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00789","article-title":"Current and emerging biomarkers predicting bone metastasis development","volume":"10","author":"Iuliani","year":"2020","journal-title":"Front Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1959101\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T08:40:15Z","timestamp":1789634415000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1959101\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":135,"alternative-id":["10.3389\/fimmu.2026.1959101"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1959101","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"article-number":"1959101"}}